Xbrane Biopharma releases 2016 Year End Report
Xbrane Biopharma ABs Year End Report for 2016 is now available on the Company’s website, www.xbrane.com. October – […]
Xbrane Biopharma reports positive in-vitro biosimilarity data on Xlucane
Xbrane Biopharma has performed a comprehensive in-vitro biosimilarity study with several pilot scale R&D batches of Xlucane versus […]
OrganoClick AB (publ) publish Year end report 2016
The fourth quarter was a strong end to the year, with organic sales growth for the group of […]
Summary from extraordinary general meeting of Episurf Medical AB (publ)
Episurf Medical AB (publ) held an extraordinary general meeting on 20 February 2017 at which it was resolved, […]
At Serendipity, we are proud of our heritage and we embrace our serendipitous beginnings. So much so, that it is a fundamental element in our philosophy and the way we work.
For more than a decade, Serendipity has focused on transforming cutting edge technologies into products and services that bring value to the world. Ranging from environmentally friendly alternatives to existing products to novel products that pave the way and set new standards in their respective fields, we seek to build sustainable businesses with global markets.
Net Asset Value per Share
Net Asset Value
Varmt välkommen till Serendipity Ixoras årsstämma 2017. Datum: Onsdagen den 7 juni 2017 För mer information vänligen kontakta: Amin […]
Informations- och uppdateringsseminarium 1 december 2016
Varmt välkommen till Serendipity Ixoras informations- och uppdateringsseminarium som äger rum torsdagen den 1 december 2016. Platsen för […]
Quarterly update Q1 2017
The Serendipity Ixora Q1 quarterly update will be published on the company website: 2017-04-17
We identify, develop, and invest in leading innovative technologies and companies with the ability to make global impact on societal and industrial grand challenges. As such, our portfolio companies combine disruptive technologies and trends with strong and competent teams aiming for global markets.
Each new investment is evaluated in terms of market potential, scalability, distinct competitive advantage, high differentiation, strong leadership, and the ability to deliver high margins over time.
We build to keep. Therefore we have no explicit exit strategy, provided that the company continues to generate growth in line with our targets.